A world-leading Melbourne innovation is rapidly changing the way cell therapies are manufactured to treat diseases including stroke and cerebral palsy, taking these treatments out of the lab and into hospitals.

The new cell-processing technology, ROTEA, developed by Melbourne start-up, Scinogy in conjunction with Hudson Institute of Medical Research, is significantly reducing the costs and labour associated with manufacturing cells for clinical use.

“This is game changer for the health and cell therapies sectors. The technology significantly reduces manufacturing costs, and our hope is that it means more patients can access the benefits of cell therapies,” said Scinogy CEO, David James.